Physician profile
Jonathan Warren
NPI 1760601280
$1,872.33
in general payments reported to CMS, 2019-2025
18 companies · $80.47 in 2025
The $80.47 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $515 · 2023: $791 · 2024: $216 · 2025: $80.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $568.99 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $216.14 | 2021-2023 | |
| Amgen INC. | $193.03 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $173.82 | 2021-2023 | Brilinta, Farxiga |
| Pfizer INC. | $85.48 | 2022-2023 | |
| Boston Scientific Corporation | $82.05 | 2022-2025 | Watchman Flx, Accolade Sr |
| Actelion Pharmaceuticals US, INC. | $70.08 | 2022-2023 | Opsumit |
| Impulse Dynamics (USA) INC. | $69.11 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $66.74 | 2021-2022 | |
| Esperion Therapeutics, INC. | $64.73 | 2021-2023 | Nexletol |
| Abbott Laboratories | $60.05 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $51.49 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $49.89 | 2021-2022 | |
| Celgene Corporation | $30.58 | 2022-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $29.87 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $20.89 | 2024 | |
| Merck Sharp & Dohme LLC | $20.65 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.74 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.